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The mitotic checkpoint (also known as the spindle assembly 
checkpoint) is the major cell cycle control mechanism during   
mitosis and acts to prevent chromosome missegregation and its 
accompanying aneuploidy (Fig. 1 A). The signaling pathway is 
partially established; kinetochores on unattached chromosomes 
generate an inhibitor that binds to Cdc20, the substrate specificity 
factor of the anaphase-promoting complex (APC), an E3 ubiqui-
tin  ligase.  Cdc20  activates  recognition  by APC  of  substrates 
whose ubiquitination is required for chromosome segregation 
during anaphase, including cyclin B and securin. The mitotic 
checkpoint proteins Mad2, BubR1, and a complex containing 
both, have all been shown to bind directly to Cdc20, thereby   
inhibiting APC-mediated ubiquitination of cyclin B and securin 
and blocking anaphase initiation. Six mouse models expressing 
reduced  levels  of  mitotic  checkpoint  proteins  (Mad1,  Mad2, 
Bub1, BubR1, Bub3, and centromere protein E [CENP-E]), as 
well as mice overexpressing Mad2, have previously been shown 
to produce elevated rates of chromosome missegregation (Dobles 
et al., 2000; Babu et al., 2003; Baker et al., 2004; Iwanaga et al., 
2007; Jeganathan et al., 2007; Perera et al., 2007; Sotillo et al., 
2007; Weaver et al., 2007). However, these animals exhibit high 
variability in spontaneous tumor development. In this framework, 
Li et al. (see p. 983 of this issue) now report that mice expressing 
a  dominant  mutant  in  Cdc20,  the  factor  whose  activity  is   
targeted by the mitotic checkpoint signaling pathway, exhibit   
aneuploidy and a remarkably high tumor incidence.
Impaired mitotic checkpoint signaling can both promote 
and  suppress  tumors.  The  mitotic  checkpoint  targets 
Cdc20, the specificity factor of the ubiquitin ligase that 
promotes anaphase by targeting cyclin B and securin for 
destruction.  In  this  issue,  Li  et  al.  (2009.  J.  Cell  Biol. 
doi:10.1083/jcb.200904020) use gene replacement to 
produce  mice  expressing  a  Cdc20  mutant  that  cannot   
be inhibited by the mitotic checkpoint. In addition to the 
expected aneuploidy, these animals have a high tumor   
incidence that is likely caused by persistent aneuploidy 
coupled with nonmitotic functions of mutant Cdc20.
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Li et al. (2009) designed a Cdc20 mutant that would not 
interact with Mad2 by mutating to alanine two charged resi-
dues and a proline in the Mad2-binding site. Interestingly, this 
mutant (Cdc20
AAA) also displays significantly reduced bind-
ing to both of its sites on BubR1, so much so that overexpres-
sion of BubR1 cannot rescue the mitotic checkpoint defect   
in Cdc20
AAA/AAA cells. Thus, Cdc20
AAA cannot be inhibited by 
the mitotic checkpoint. As predicted, its presence results in   
aneuploidy from chromosomal instability (CIN), the recurrent 
missegregation  of  chromosomes  during  multiple  divisions. 
Mice expressing the Cdc20
AAA mutant develop tumors rapidly, 
with 50% of mice developing tumors, some palpable as early 
as 7 mo.
Earlier analyses of mice with reduced levels of mitotic 
checkpoint components have come to divergent outcomes vis a 
vis aneuploidy driving tumorigenesis (Fig. 1). Reduced levels 
of Bub3 (Baker et al., 2006) and BubR1 (Baker et al., 2004) do 
not produce an increase in spontaneous tumors, but about a 
quarter of mice with half the normal levels of Mad1 (Iwanaga   
et al., 2007), Mad2 (Michel et al., 2001), or CENP-E (Weaver   
et al., 2007) develop spontaneous tumors late in life (≥18 mo of 
age; Fig. 1 B). A higher proportion (50%) of mice expressing 
reduced levels of Bub1 (Jeganathan et al., 2007) or high levels 
of Mad2 (Sotillo et al., 2007) develop tumors, many with a short 
latency (Fig. 1 C).
Although it was initially tempting to attribute the differing 
tumor incidence in mice with weakened mitotic checkpoint sig-
naling to disparate levels of aneuploidy, the combined evidence 
does not support this conclusion. The percentage of aneuploid 
cells in fibroblasts and/or splenocytes in these models is similar, 
whereas tumorigenesis is not. Therefore, what seems most plau-
sible is that aneuploidy drives a high incidence of tumorigenesis 
only if the reduction or overexpression of specific mitotic check-
point components produces other defects that predispose them to 
tumors, such as an increase in DNA damage, chromosomal rear-
rangements, and/or a decreased incidence of cell death (Fig. 1 C). 
There is persuasive evidence underlying this conclusion. Roles 
outside  mitosis  are  known  or  implicated  for  several  mitotic 
checkpoint components. Mad1 is involved in nuclear import, 
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chromosome segregation. Thus, it is likely that the modest   
increase in spontaneous tumorigenesis from reduced levels of 
CENP-E represents the true contribution of whole chromosomal 
aneuploidy in driving tumorigenesis.
An increase in whole chromosomal aneuploidy does pro-
mote tumors in some contexts, presumably the result of an   
imbalance of gene expression (Duesberg et al., 2006), gain of 
oncogenes, and/or loss of tumor suppressors. However, aneu-
ploidy does not always promote tumorigenesis, and aneuploid 
animals are largely indistinguishable from wild-type animals 
for most of their lifespan. Most intriguingly, aneuploidy can 
suppress tumors in certain contexts. Reduction of BubR1 sup-
presses tumor formation in the small intestine of mice express-
ing the multiple intestinal neoplasia allele of the Apc tumor 
suppressor (Rao et al., 2005). Further reduction of Bub1 (to 
20% of the wild-type level) causes a decreased incidence of 
spontaneous liver tumors (Jeganathan et al., 2007). Hetero-
zygous deletion of CENP-E suppresses tumors in three distinct 
contexts: spontaneous liver tumors, tumors caused by the car-
cinogen DMBA (9,10-dimethyl-1,2-benzanthracene), and tumors 
caused by loss of the tumor suppressor p19ARF (Weaver et al., 
2007).  Thus,  three  independent  groups,  using  three  distinct 
methods of inducing aneuploidy, have shown that aneuploidy 
can suppress tumors in five contexts (Fig. 1 D).
Aneuploidy-mediated tumor suppression is likely the result 
of high rates of CIN that cause loss of both copies of one or more 
essential chromosomes. High rates of CIN caused by complete 
depletion of Mad2 or BubR1 have been shown to cause rapid 
death in tumor cells (Kops et al., 2004; Michel et al., 2004). Cell 
death can be prevented by inhibiting cytokinesis, which is fully 
consistent with death caused by loss of ≥1 essential chromosome 
(Fig. 1 D; Kops et al., 2004). In addition, aneuploidy is growth 
suppressive in previously diploid human tumor cells (Thompson 
and Compton, 2008) and in otherwise normal mouse cells trip-
loid for chromosomes 1, 13, 16, or 19 (Williams et al., 2008).
Bub3 participates in transcriptional repression, and BubR1 func-
tions in cell death, the DNA damage response, aging, and mega-
karyopoiesis (Weaver and Cleveland, 2006). Genetic evidence 
has indicated that budding yeast homologues of Mad2, BubR1, 
and  Bub3  participate  in  gross  chromosomal  rearrangements 
(Myung et al., 2004). Consistent with this yeast evidence, Mad2 
overexpression in mouse cells drives development of numerous 
chromosomal breaks, gaps, and rearrangements (Sotillo et al., 
2007), causing DNA damage and the potential for oncogenic   
fusion proteins. The role of Bub1 in preventing cell death (Baek   
et al., 2005; Perera and Freire, 2005; Jeganathan et al., 2007) is 
likely to predispose Bub1 hypomorphic mice to tumorigenesis. 
Similarly, Mad2 has been reported as a negative regulator of 
DNA damage repair (Fung et al., 2008), predicting that Mad2-
overexpressing mice have increased DNA damage, although this 
was not directly examined (Sotillo et al., 2007). Relevant to the 
Li et al. (2009) study, Cdc20 has been reported to act as a tran-
scriptional repressor in human cells (Yoon et al., 2004). It has 
also been proposed to have roles in the DNA damage checkpoint 
(Lim and Surana, 1996) and in precipitating premature entry into 
mitosis (Clarke et al., 2003). On balance, considering the wealth 
of mouse models with mitotic checkpoint deficiencies, the exist-
ing evidence favors an interpretation in which the nonmitotic 
roles of Cdc20 have a key influence on the tumor phenotype of 
Cdc20
+/AAA mice.
The only mitotic checkpoint component for which no role 
outside of mitosis has been suggested is CENP-E. Unlike the 
other  checkpoint  components,  which  are  present  throughout   
interphase and in noncycling cells, CENP-E is tightly cell cycle 
regulated in all reported contexts. It accumulates, like the mi-
totic cyclins, just before mitosis and is quantitatively degraded at 
the end of mitosis. Its absence outside mitosis as well as failure 
to identify additional roles for CENP-E in DNA damage or chro-
mosomal rearrangements (Weaver et al., 2007) argue that the 
most plausible scenario is that CENP-E functions exclusively in 
Figure 1.  The consequences of CIN. Low rates 
of CIN promote tumors, but high rates of CIN 
cause cell death and tumor suppression. Divi-
sions in a hypothetical cell with three chromo-
somes. (A) Normal cells do not exhibit CIN 
and  produce  genetically  identical  progeny. 
(B) Animals heterozygous for the mitotic check-
point  components  Mad1,  Mad2,  or  CENP-E 
missegregate  one  or  a  few  chromosomes 
per division (low CIN) and exhibit a modest 
tumor phenotype. Approximately 20–25% of 
these animals develop late onset spontaneous 
tumors. (C) Coupling a low rate of CIN with 
another  tumor-promoting  activity,  such  as  a 
reduced rate of cell death, results in a higher 
rate of tumor formation with a shorter latency. 
(D) High rates of CIN lead to massive chromo-
some missegregation and cell death from loss 
of both copies of ≥1 essential chromosome.937 ANEUPLOIDY PROMOTES AND SUPPRESSES TUMORS • Weaver and Cleveland
A consistent theme is that missegregation of one or a few 
chromosomes per division (low CIN) promotes tumorigenesis 
(Fig. 1 B), whereas missegregation of a larger number of chro-
mosomes per division (high CIN) drives cell death and tumor 
suppression (Fig. 1 D). If this is so, what about “highly aneu-
ploid” tumor cells in which the chromosome number is signifi-
cantly >46? The current data support that acquisition of these 
highly abnormal chromosome contents occurs slowly over nu-
merous  cell  divisions  involving  more  subtle  changes,  which 
permits the cells to make any compensatory changes in gene 
expression necessary for survival.
Lastly, in human tumors, aneuploidy often occurs in cells 
that contain additional genomic changes that are likely to influ-
ence the effect of an increased rate of CIN. The interplay be-
tween aneuploidy and specific additional defects is now one of 
the key unresolved questions that will be needed to predict, in a 
given context, whether increasing the rate of CIN will promote 
tumors, suppress tumors, or neither.
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